DE69330351T2 - 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten - Google Patents

5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten

Info

Publication number
DE69330351T2
DE69330351T2 DE69330351T DE69330351T DE69330351T2 DE 69330351 T2 DE69330351 T2 DE 69330351T2 DE 69330351 T DE69330351 T DE 69330351T DE 69330351 T DE69330351 T DE 69330351T DE 69330351 T2 DE69330351 T2 DE 69330351T2
Authority
DE
Germany
Prior art keywords
ylmethyl
indol
benzimidazole
alkyl
methylpyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330351T
Other languages
German (de)
English (en)
Other versions
DE69330351D1 (de
Inventor
Eugene Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Inc filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of DE69330351D1 publication Critical patent/DE69330351D1/de
Publication of DE69330351T2 publication Critical patent/DE69330351T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DE69330351T 1992-11-02 1993-10-19 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten Expired - Fee Related DE69330351T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
PCT/US1993/009790 WO1994010171A1 (en) 1992-11-02 1993-10-19 5-arylindole derivatives and their use as serotonin (5-ht1) agonists

Publications (2)

Publication Number Publication Date
DE69330351D1 DE69330351D1 (de) 2001-07-19
DE69330351T2 true DE69330351T2 (de) 2001-09-20

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330351T Expired - Fee Related DE69330351T2 (de) 1992-11-02 1993-10-19 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten

Country Status (27)

Country Link
US (1) US5886008A (OSRAM)
EP (2) EP1094064A1 (OSRAM)
JP (1) JP2788551B2 (OSRAM)
KR (1) KR0163371B1 (OSRAM)
CN (1) CN1051313C (OSRAM)
AT (1) ATE202102T1 (OSRAM)
AU (1) AU685066B2 (OSRAM)
BR (1) BR9307348A (OSRAM)
CA (2) CA2148380C (OSRAM)
CZ (1) CZ283001B6 (OSRAM)
DE (1) DE69330351T2 (OSRAM)
DK (1) DK0666858T3 (OSRAM)
EG (1) EG20396A (OSRAM)
ES (1) ES2157224T3 (OSRAM)
FI (2) FI111257B (OSRAM)
GR (1) GR3036579T3 (OSRAM)
HU (1) HU222235B1 (OSRAM)
IL (1) IL107386A (OSRAM)
MY (1) MY109696A (OSRAM)
NO (1) NO309652B1 (OSRAM)
NZ (1) NZ257059A (OSRAM)
PL (1) PL176091B1 (OSRAM)
PT (1) PT666858E (OSRAM)
RU (1) RU2134266C1 (OSRAM)
TW (1) TW251284B (OSRAM)
WO (1) WO1994010171A1 (OSRAM)
ZA (1) ZA938137B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
CZ59996A3 (en) * 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
WO1995021836A1 (en) * 1994-02-10 1995-08-17 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
CA2234166A1 (en) * 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
AU2004268950A1 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine-derivatives as c-kit inhibitors
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
ES2346157T3 (es) * 2006-03-22 2010-10-11 Janssen Pharmaceutica N.V. Derivados de alquilaminas ciclicas como inhibidores de la interaccion entre mdm2 y p53.
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
WO2016176449A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
AU2016256413B2 (en) 2015-04-29 2020-10-08 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
WO2016176457A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
DK3288940T5 (da) 2015-04-29 2021-09-20 Janssen Pharmaceutica Nv Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
CR20180255A (es) 2015-11-06 2018-06-22 Hoffmann La Roche Derivados de indolin-2-ona
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
KR0179053B1 (ko) * 1990-10-15 1999-03-20 알렌 제이.스피겔 인돌 유도체
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
ES2157224T3 (es) 2001-08-16
CA2340999C (en) 2005-01-04
NO951633D0 (no) 1995-04-28
CN1094727A (zh) 1994-11-09
HUT66011A (en) 1994-08-29
NZ257059A (en) 1997-07-27
PL308669A1 (en) 1995-08-21
CZ283001B6 (cs) 1997-12-17
EP0666858A1 (en) 1995-08-16
RU2134266C1 (ru) 1999-08-10
CZ110895A3 (en) 1995-11-15
JP2788551B2 (ja) 1998-08-20
IL107386A (en) 1999-03-12
MY109696A (en) 1997-04-30
FI111257B (fi) 2003-06-30
IL107386A0 (en) 1994-01-25
EG20396A (en) 1999-02-28
WO1994010171A1 (en) 1994-05-11
PL176091B1 (pl) 1999-04-30
EP0666858B1 (en) 2001-06-13
GR3036579T3 (en) 2001-12-31
ZA938137B (en) 1995-05-02
RU95109927A (ru) 1997-01-10
KR950704313A (ko) 1995-11-17
BR9307348A (pt) 1999-05-11
FI20002505L (fi) 2000-11-15
FI20002505A7 (fi) 2000-11-15
NO309652B1 (no) 2001-03-05
KR0163371B1 (ko) 1998-12-01
DK0666858T3 (da) 2001-08-27
US5886008A (en) 1999-03-23
DE69330351D1 (de) 2001-07-19
CA2148380C (en) 2001-08-14
FI934825L (fi) 1994-05-03
HU222235B1 (hu) 2003-05-28
EP1094064A1 (en) 2001-04-25
FI934825A0 (fi) 1993-11-01
JPH07508759A (ja) 1995-09-28
CA2148380A1 (en) 1994-05-11
CA2340999A1 (en) 1994-05-11
ATE202102T1 (de) 2001-06-15
NO951633L (no) 1995-04-28
AU685066B2 (en) 1998-01-15
AU5329494A (en) 1994-05-24
TW251284B (OSRAM) 1995-07-11
CN1051313C (zh) 2000-04-12
PT666858E (pt) 2001-09-28

Similar Documents

Publication Publication Date Title
DE69330351T2 (de) 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten
DE69230803T2 (de) 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
DE69413240T2 (de) 5-arylindolderivate
DE69132691T2 (de) Indolderivate als 5-HT1-like Agonisten
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
DE69127468T2 (de) Indolderivate
DE69331988T2 (de) Indol derivate als 5-ht1 agoniste
DE69028934T2 (de) Tetrahydrobenzimidazol-Derivate
DE69307875T2 (de) Acylaminoindolderivate als 5-ht1 agonisten
US5053511A (en) 1,3-dihydro-1-(pyridinylamino)-2h-indol-2-ones
DE69323667T2 (de) 4-substituierte 1,2,4-Triazolderivate
JPH07506825A (ja) ５−ｈｔ１レセプターアゴニストとしての縮合イミダゾール及びトリアゾール誘導体
NZ228721A (en) Substituted indoles and indazoles and pharmaceutical compositions
DE69221652T2 (de) Substituiertes cyclisches Sulfamidderivat
DE69329645T2 (de) Imidazol-, triazol- und tetrazolderivate
DE69425510T2 (de) 3-substituierte 1-arylindolverbindungen
DE69521295T2 (de) Triazolderivate
US5621116A (en) 1-amino-3,3-bis(thienylalkyl)-1,3-dihydro-2H-indol-2-ones
US5994352A (en) 5-arylindole derivatives
JPWO1993020077A1 (ja) 縮合キノキサリノン誘導体及びその医薬組成物

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee